Keystone Bio has identified and is targeting a "one of a kind Inflammapath ", the keystone pathogen of chronic inflammation that’s been shown to initiate and advance Atherosclerosis, Heart disease and Alzheimer's disease.Keystone Bio is a nextgen PharmaBiome biotech that has identified and is targeting a "one of a kindInflammapath ", the keystone pathogen of chronic inflammation that’s been shown to initiate and advance Atherosclerosis, Heart disease and Alzheimer's disease.

Pharmaceutical

Health Care

Biotechnology

Keystone Bio

Daniel Sindelar DMD

Peter Nara

Jim Klein

Michael Rafii

Marc Penn

Advisory Team

Leadership Team

Teams at Keystone Bio

Advisory Team

Leadership Team